Literature DB >> 12466143

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Lin Zhang1, Nuo Yang, Jose-Ramon Conejo Garcia, Alisha Mohamed, Fabian Benencia, Stephen C Rubin, David Allman, George Coukos.   

Abstract

Vascular endothelial growth factor (VEGF) performs multifaceted functions in the tumor microenvironment promoting angiogenesis, suppressing anti-tumor immune response, and possibly exerting autocrine functions on tumor cells. However, appropriate syngeneic animal models for in vivo studies are lacking. Using retroviral transfection and fluorescence-activated cell sorting, we generated a C57BL6 murine ovarian carcinoma cell line that stably overexpresses the murine VEGF164 isoform and the enhanced green fluorescent protein. VEGF164 overexpression dramatically accelerated tumor growth and ascites formation, significantly enhanced tumor angiogenesis, and substantially promoted the survival of tumor cells in vivo. In vitro, VEGF164 overexpression significantly enhanced cell survival after growth factor withdrawal and conferred resistance to apoptosis induced by cis-platin through an autocrine mechanism. VEGF/green fluorescent protein-expressing tumors were not recognized by the adaptive immune system. After vaccination, a specific anti-tumor T-cell response was detected, but tumor growth was not inhibited. This engineered murine carcinoma model should prove useful in the investigation of the role of VEGF in modulating the tumor microenvironment and affecting the complex interactions among angiogenesis mechanisms, anti-tumor immune mechanisms, and tumor cell behavior at the natural state or during therapy in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466143      PMCID: PMC1850900          DOI: 10.1016/s0002-9440(10)64505-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  73 in total

1.  In vitro analysis of transformation potential associated with retroviral vector insertions.

Authors:  S K Powell; M Kaloss; I Burimski; L Weaver; Z Long; R Lyons; G J McGarrity; E Otto
Journal:  Hum Gene Ther       Date:  1999-09-01       Impact factor: 5.695

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

3.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

4.  Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells.

Authors:  C Herold-Mende; H H Steiner; T Andl; D Riede; A Buttler; C Reisser; N E Fusenig; M M Mueller
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

Review 5.  Prognostic value of vascular endothelial growth factor in breast cancer.

Authors:  G Gasparini
Journal:  Oncologist       Date:  2000

6.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

7.  Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer.

Authors:  J Itakura; T Ishiwata; B Shen; M Kornmann; M Korc
Journal:  Int J Cancer       Date:  2000-01-01       Impact factor: 7.396

8.  Tumor angiogenesis factors reduce leukocyte adhesion in vivo.

Authors:  S C Tromp; M G oude Egbrink; R P Dings; S van Velzen; D W Slaaf; H F Hillen; G J Tangelder; R S Reneman; A W Griffioen
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

9.  Clinical significance of defective dendritic cell differentiation in cancer.

Authors:  B Almand; J R Resser; B Lindman; S Nadaf; J I Clark; E D Kwon; D P Carbone; D I Gabrilovich
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

10.  Development of a syngeneic mouse model for events related to ovarian cancer.

Authors:  K F Roby; C C Taylor; J P Sweetwood; Y Cheng; J L Pace; O Tawfik; D L Persons; P G Smith; P F Terranova
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

View more
  61 in total

1.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

3.  Involvement of endothelial CD44 during in vivo angiogenesis.

Authors:  Gaoyuan Cao; Rashmin C Savani; Melane Fehrenbach; Chris Lyons; Lin Zhang; George Coukos; Horace M Delisser
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Authors:  Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

5.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

6.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

7.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

8.  A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2.

Authors:  Fumikata Hara; Shaija Samuel; Jinsong Liu; Daniel Rosen; Robert R Langley; Honami Naora
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Authors:  Ioannis Alagkiozidis; Andrea Facciabene; Carmine Carpenito; Fabian Benencia; Zdenka Jonak; Sarah Adams; Richard G Carroll; Phyllis A Gimotty; Rachel Hammond; Gwen-äel Danet-Desnoyers; Carl H June; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2009-12-10       Impact factor: 5.531

10.  Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer.

Authors:  Xiaolong Zou; Haiquan Qiao; Xian Jiang; Xuesong Dong; Hongchi Jiang; Xueying Sun
Journal:  J Biomed Sci       Date:  2008-12-25       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.